Stay updated with breaking news from Technologies Munich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bruce Power says it’s closer to producing the medical isotope Lutetium-177, used to target cancers such as neuroendocrine tumours and prostate cancers.
The latest nuclear news in Nuclear Power Industry about utilities, companies, suppliers in the nuclear energy market.
Bruce Power announced this week it’s closer to producing the medical isotope Lutetium-177, used to target cancers such as neuroendocrine tumours and prostate…
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the